Global Botulism Treatment Market, By Type (Food Borne Botulism, Infant Botulism, Inhalation Botulism, Wound Botulism and Others), Treatment (Anti Toxin, Antibiotics and Others), End-Users (Veterinary Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Botulism Treatment Market Analysis and Size
Botulinum toxin is one of the most exceptional substances that is witnessed in medicine and science. The wide adoption of botulinum toxin in cosmetology has grown rapidly over the decade. Currently, it is one of the most common and widely performed aesthetic procedures in the world. It has been seen that without early treatment, botulism can lead to paralysis, breathing challenges, and death. Botulinum toxin was consequently authorized for the treatment of several spasticity problems along with a variety of other ailments. It is currently utilized in practically all medical subspecialties.
Data Bridge Market Research analyses a growth rate in the botulism treatment market in the forecast period 2023-2030. The expected CAGR of botulism treatment market is tend to be around 6.50% in the mentioned forecast period. The market was valued at USD 0.96 billion in 2022, and it would grow upto USD 1.6 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Botulism Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Food Borne Botulism, Infant Botulism, Inhalation Botulism, Wound Botulism and Others), Treatment (Anti Toxin, Antibiotics and Others), End-Users (Veterinary Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
XOMA Corporation (U.S.), Microbiotix (U.S.), Bausch Health Companies Inc (Canada), Eisai Inc. (U.S.), Merz Pharma (Germany), GALDERMA (Switzerland), Abbvie, Inc (U.S.), Molecular Targeting Technologies, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Botulism is a type of disorder that is characterized by a paralytic illness caused by neurotoxin clostridium botulinum. Botulism seems to directly affect nerve function and blocks its functioning if left untreated for a longer period. The rare complications associated with it are weakness of chest muscles, arms and legs. A person can be infected only by ingestion of contaminated food, or a toxin drug injected that leads to wound botulism. Common symptoms include double vision, dropping of both eyelids, nausea, swallowing problems, lass of facial expression, vomiting and constipation.
Global Botulism Treatment Market Dynamics
Drivers
- Increase in Elderly Population
The botulism treatment market is projected to witness a heavy growth rate in the forecast period driven by the factor of an aging population. The increasing demand in the global market is the replication of the rising elderly population, as people aged over 60 years frequently develop low immunity conditions, affecting the normal functioning. This boost the market growth.
- Growing Cases of Botulism
As per the statistics of the Centers for Disease Control and Prevention (CDC), in 2017, 182 confirmed cases of botulism were reported in the U. S., out of which 77% were infant botulism, 10% were foodborne botulism, 10% were wound botulism, and 1% were other types. Additionally, an increase in botulism occurrence rate is projected to drive the global botulism market..
Opportunities
- Higher Development of Botulinum Products
The wide availability of a variety of botulinum toxin products such as Botox, Xeomin, and disport will increase the market growth. The growing usage of botulinum toxin injection in numerous aesthetic procedures, including the treatment of glabellar lines, chemical browlift, and forehead lines is anticipated to boost the market growth over the coming years. Presently, a few products of botulinum toxin–Type-A and only one product of Type-B (Myobloc) are commercially available in the market.
- Increased Technological Advancements
Technological advancements in the healthcare industry have led to the introduction of various types of antitoxin and antibiotics for the treatment of botulism. Large number of R&D initiatives and the availability of new solutions are anticipated to be the major drivers of the global botulism market during the forecast period.
Restraints/Challenges
- Side Effects of Botulism Treatment
Various side effects are associated with botulism treatment such as chest pain or discomfort, difficulty with breathing, and inflammation of the joints. Thus, all these factors hamper the market growth.
- High Cost
The huge expenditure associated with the treatment of botulism hamper the market growth. The treatment becomes quite unaffordable in middle-income countries, thus, in a way restricting the market growth.
This botulism treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the botulism treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth
Recent Developments:
- In 2021, Maypharm announced a new botulinum toxin, METOX. METOX is an effective solution for smoothing any wrinkles from moderate to severe caused by daily active facial movements
- In 2021, Sihuan Pharmaceutical Holdings Group Ltd. received approval for launching the botulinum toxin product Letybo50U.
Global Botulism Treatment Market Scope
The botulism treatment market is segmented on the basis of type, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Food Borne Botulism
- Infant Botulism
- Inhalation Botulism
- Wound Botulism
- Others
Treatment
- Anti Toxin
- Antibiotics
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Botulism Treatment Market Regional Analysis/Insights
The botulism treatment market is analyzed and market size insights and trends are provided by type, treatment, distribution channel and end-user as referenced above.
The major countries covered in the botulism treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for botulism treatment market throughout the forecasted period due to increased new research and developments on botulism treatment market.
North America dominates the market due to the presence of key manufacturers of the product is high and, increasing research and development activities, healthcare expenditure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Botulism Treatment Market Share Analysis
The botulism treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to botulism treatment market.
Key players operating in the botulism treatment market include:
- XOMA Corporation (U.S.)
- Microbiotix (U.S.)
- Bausch Health Companies Inc (Canada)
- Eisai Inc. (U.S.)
- Merz Pharma (Germany)
- GALDERMA (Switzerland)
- Abbvie, Inc (U.S.)
- Molecular Targeting Technologies, Inc. (U.S.)
SKU-